MDMA in PTSD therapy - what phase 3 studies really showed
MDMA w terapii PTSD — co to, co mowia badania i status prawny w Polsce. u Bucha.
For decades, MDMA - commonly known as ecstasy - was associated solely with electronic music and parties. In 2023, the same substance made headlines Nature Medicine as a potential breakthrough in the treatment of one of the most difficult-to-treat psychiatric disorders: post-traumatic stress disorder. Two phase 3 studies conducted by MAPS demonstrated the effectiveness of MDMA-assisted therapy at a level rarely achieved in psychopharmacology. At the same time, in 2024, the FDA refused to register the drug - for methodological reasons, not because the drug does not work. This article explains what the studies really showed, where their limitations lie, and what the legal context is in Poland.
KEY INFORMATION
• Phase 3 studies MAPP1 and MAPP2 (Nature Medicine, 2023) showed remission of PTSD in 67-71% of patients taking MDMA vs. 32-48% in placebo - with the same psychotherapy (Mitchell et al., Nature Medicine, 2023).
• The FDA refused approval in August 2024 for methodological reasons, not due to lack of efficacy - additional data were requested.
• MDMA is a controlled substance group I-P in Poland - possession is illegal, and there are no legal therapeutic programs.
• MDMA therapy is a clinical protocol conducted by trained therapists - it is not self-administration of the substance.
What is MDMA-assisted therapy and how does it differ from recreational use?
MDMA-assisted therapy (MDMA-Assisted Therapy, MDMA-AT) is a precise clinical protocol that has nothing to do with recreational use of the substance. The MAPS protocol includes 12 weeks and three elements: preparatory sessions (without the substance, establishing a therapeutic relationship), 2-3 extended sessions with MDMA (6-8 hours each, in a clinically supervised environment), and integration sessions after each experience (MAPS Therapeutic Protocol, 2022).
MDMA acts on the brain in a way unique to this substance: it massively releases serotonin, dopamine, and norepinephrine while strongly stimulating the release of oxytocin. The key clinical effect is a temporary reduction in the reactivity of the amygdala - the center responsible for anxiety and threat responses - while maintaining full awareness and the ability to converse. This unique psychopharmacological state creates a "therapeutic window" in which the patient can reprocess traumatic memories without triggering a full stress response.
This is a fundamental difference compared to recreational use of MDMA, where the effect is completely different: lack of therapeutic context, different set of attitudes, different environment, different dosage, and frequency of use. MAPS clinical studies are evidence of the effectiveness of a specific protocol - not of the effectiveness of MDMA as a substance taken alone.
Results of phase 3 studies MAPP1 and MAPP2 - detailed analysis
Two phase 3 studies - MAPP1 and MAPP2 - were randomized, double-blind (with active placebo), multicenter studies involving patients with moderate or severe PTSD. The results of MAPP1 were published in 2021, and the results of both studies in a pooled analysis in Nature Medicine 2023 (Mitchell et al., Nature Medicine, 2023).
The primary endpoint is the change in the CAPS-5 scale (Clinician-Administered PTSD Scale, version 5) - the gold standard for measuring PTSD severity in clinical trials. In MAPP1: MDMA-AT reduced the CAPS-5 score by 24.4 points vs. 13.9 points in placebo (difference of 10.5 points, p<0.001). In MAPP2, the results were similar. Clinically significant improvement defined as a change of ≥10 points - both intervention groups exceeded this threshold with a significant advantage over placebo.
| Parameter | MDMA-AT | Placebo+therapy |
|---|---|---|
| PTSD remission (no diagnosis after treatment) | 67-71% | 32-48% |
| Change in CAPS-5 (MAPP1) | −24.4 points | −13.9 points |
| Response to treatment (≥12 points improvement) | ~88% | ~60% |
| Maintenance of effect (12 months) | Tak - potwierdzono w long-term follow-up | Limited data |
We noted that the context of the control group is particularly important here. Patients in the placebo group also received psychotherapy - and also achieved impressive improvement (~40-48% remission). This shows that high-quality trauma psychotherapy alone is effective. MDMA doubles or triples these results - this is the measure of the added value of the substance. For patients resistant to other treatment methods, this difference is clinically groundbreaking.
Why did the FDA refuse approval in 2024?
In August 2024, the FDA issued a Complete Response Letter (CRL) to Lykos Therapeutics (spun off from MAPS), denying the registration of MDMA as a treatment for PTSD. This decision surprised many communities, but it had substantive grounds that are worth understanding (Yazar-Klosinski et al., J Psychopharmacol, 2025).
Three main concerns of the FDA: first, the issue of blinding. MDMA produces characteristic subjective effects, so most participants knew which group they belonged to - which could systematically inflate subjective ratings of improvement. Second, the heterogeneity of session quality: effects varied significantly between research centers, suggesting that outcomes strongly depend on the therapists' competencies - creating a challenge for standardization in potential clinical implementation. Third, concerns about long-term safety and potential for abuse.
Importantly: the FDA did not question the efficacy of MDMA-AT as such. It requested additional studies aimed at better methodological control, rather than proving efficacy anew. The decision is a step back on the timeline, not a definitive closing of the door. New studies are in the planning stages.
Legal status in Poland and harm-reduction context
In Poland, MDMA is a controlled substance, listed in the schedule of narcotic and psychotropic substances of group I-P under the Act on Counteracting Drug Addiction (Journal of Laws 2023, item 1939). Possession, production, and trade of MDMA are illegal without a special permit from the Chief Pharmaceutical Inspector. There are no legal therapeutic programs involving MDMA in Poland - the substance is available only in strictly controlled clinical trials conducted under regulatory approval.
From a harm-reduction perspective, it is important for individuals interested in the therapeutic potential of MDMA to understand a fundamental distinction: phase 3 study results pertain to a strictly defined clinical protocol with prepared therapists, a controlled environment, and integration. Taking MDMA independently without this context does not replicate the conditions of clinical trials and carries serious health risks - including cardiovascular, psychological, and legal risks.
From our editorial experience: the topic of MDMA-AT attracts individuals with PTSD who have exhausted standard treatment options. We understand this perspective - treatment-resistant PTSD is a debilitating condition. That is why reliable information is particularly important here: not to discourage following research progress, but to protect against decisions based on incomplete information.
What’s next for MDMA therapy - perspectives after the FDA decision?
The FDA's refusal in August 2024 slowed but did not halt the registration process. Lykos Therapeutics announced its intention to respond to the CRL after supplementing the data - planned for 2025-2026. At the same time, several other pharmaceutical entities (Empath Biosciences, MindMed, Multidisciplinary Association for Psychedelic Studies) are working on alternative protocols with MDMA or its analogs that may address the identified methodological issues.
Two main methodological challenges - blinding and therapist standardization - are being addressed in new protocols. Proposed solutions to the blinding issue include using an active placebo with a more similar subjective profile (e.g., methylenedioxy-norephedrine) and more rigorous endpoint assessment procedures by evaluators who do not know which group the patient belongs to. The problem of therapist heterogeneity is being tackled by introducing more structured and certified training protocols.
In Europe, the Committee for Medicinal Products for Human Use (CHMP) of the EMA is conducting its own assessment - independently of the FDA. The European decision may come before or after the resubmission in the USA. Several European countries (Switzerland, the Netherlands) have their own, more flexible regulatory pathways for psychedelic therapies under named-patient or expanded access programs, which patients in exceptionally severe cases of PTSD can utilize.
For patients with treatment-resistant PTSD in Poland, the real pathways remain primarily: access to specialized trauma treatment centers offering EMDR and prolonged exposure (PE), transcranial psychiatry (TMS, ECT in selected cases), and monitoring the registry of active clinical trials on ClinicalTrials.gov - some of which recruit participants from Central Europe.
Frequently Asked Questions
What is MDMA-assisted therapy and how does it work?
MDMA-assisted therapy is a clinical protocol combining psychotherapy with 2-3 sessions of MDMA (6-8 hours each). MDMA reduces the reactivity of the amygdala, creating a 'therapeutic window' that allows for trauma processing without paralyzing anxiety responses. Serotonergic and oxytocinergic effects promote openness and trust in the therapist during sessions (Mitchell et al., Nature Medicine, 2023).
What did the MAPS phase 3 studies show regarding MDMA and PTSD?
Two phase 3 studies (MAPP1 and MAPP2, totaling about 200 patients) showed remission of PTSD in 67-71% in the MDMA group vs. 32-48% in placebo+therapy. The change in the CAPS-5 scale was −24.4 vs. −13.9 points. The effects persisted in a 12-month follow-up (Mitchell et al., Nature Medicine, 2023).
Why did the FDA not approve MDMA in 2024?
In August 2024, the FDA issued a Complete Response Letter with methodological concerns: the issue of participant blinding (the subjective effects of MDMA are recognizable), heterogeneity of results between centers, and limited data on long-term safety. Efficacy was not questioned - additional studies were requested.
What is the legal status of MDMA in Poland?
MDMA is a controlled substance of group I-P under the Act on Counteracting Drug Addiction (Journal of Laws 2023). Possession, production, and trade are illegal. In Poland, there are no legal therapeutic programs involving MDMA - the substance is available only in clinical trials under special permission from the GIF.
For whom can MDMA therapy be particularly effective?
The study involved patients with severe or moderate treatment-resistant PTSD (after failing at least two other therapies). The results were particularly strong in cases of complex trauma and the dissociative subtype of PTSD. The protocol is not intended for individuals with active psychosis, type I bipolar disorder, or active substance dependence.
This article is for informational and educational purposes and does not replace consultation with a doctor. If you are pregnant, breastfeeding, taking medications, or have chronic conditions, consult the use of supplements or herbs with a specialist.
Author: Michał Waluk · Published: 2026-05-04 · Updated: 2026-05-04
